Skip to main content

Advertisement

SpringerLink
Log in

The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

MicroRNAs can regulate many biological functions. miR-122-5p has a tumor suppressor function through different molecular pathways. Also, our second hit, ADAM10, targeted by miR-122-5p, is a major determinant of HER2 shedding causing that trastuzumab cannot bind to HER2 receptors. Therefore, our analysis upon ADAM10 expression and miR-122-5p was a good point to understand molecular mechanism of breast cancer. In our study, we investigated the expression profiles of miR-122-5p and its target ADAM10 in 71 breast cancer patients. Immunohistochemical analysis of ER, PR and HER2 gene products was used to categorize tumors in patients. Expression data and immunohistochemical findings were evaluated to comment on the relationship between miR-122-5p and ADAM10. ADAM10 expression was higher in tumor than that of normal tissue but miR-122-5p expression was lower in tumor than that of normal tissue. The expression pattern in HER2+ patients was reverse of the overall result. It can be explained like that miR-122-5p expression increases especially in HER2+ cancer cell to suppress ADAM10 shedding activity on HER2 receptor. However, increase in expression of tumor suppressor miR-122-5p is not enough to inhibit ADAM10. All in all, we can think miR-122-5p as potential regulator of ADAM10 and trastuzumab resistance. Since if we increase miR-122-5p activity together with trastuzumab administration, then HER2+ breast cancer cells may overcome trastuzumab resistance by inhibiting ADAM10 shedding activity on HER2 receptors and increase the efficiency of trastuzumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yang M, Chen J, Su F, Yu B, Su F, Lin L, Liu Y, Huang JD, Song E (2011) Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 10:117

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. World Health Organization (2002) National cancer control programmes policies and managerial guidelines, Geneva. Lancet 365:1727–1741. 2nd Edition

  3. Parkin DM, Fernandez LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12(Suppl 1):S70–S80

    Article  PubMed  Google Scholar 

  4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752

    Article  CAS  PubMed  Google Scholar 

  5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen B, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein, Lønning PE, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874

    Article  PubMed Central  PubMed  Google Scholar 

  6. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS (2011) Microarrays in the 2010s: the contribution of microarraybased gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 13(3):212

    Article  PubMed Central  PubMed  Google Scholar 

  7. Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5(1):5–23

    Article  CAS  PubMed  Google Scholar 

  8. Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R (2013) Novel insights into breast cancer genetic variance through RNA sequencing. Sci Rep 3:2256

    Article  PubMed Central  PubMed  Google Scholar 

  9. Moldovan L, Mitroi A, Petrescu CM, Aschie M (2013) Classification of breast carcinomas according to gene expression profiles. J Med Life 6(1):14–17

    PubMed Central  CAS  PubMed  Google Scholar 

  10. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728

    Article  PubMed  Google Scholar 

  11. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790–800

    Article  CAS  PubMed  Google Scholar 

  12. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684

    Article  CAS  PubMed  Google Scholar 

  13. Pusztai L, Symmans FW, Hortobagyi GN ( 2005) Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 12(2):73–85

  14. Zabrecky J, Lam T, McKenzie S, Carney W (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266:1716–1720

    CAS  PubMed  Google Scholar 

  15. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI (1993) The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8:2917–2923

    CAS  PubMed  Google Scholar 

  16. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J (1999) Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59:1196–1201

    CAS  PubMed  Google Scholar 

  17. Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, Katiyar K, Bradley J, Abremski K, Stow M, Rupar M, Zhuo J, Li YL, Lin Q, Burns D, Xu M, Zhang C, Qian DQ, He C, Sharief V, Weng L, Agrios C, Shi E, Metcalf B, Newton R, Friedman S, Yao W, Scherle P, Hollis G, Burn TC (2006) Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 5(6):657–664

    Article  CAS  PubMed  Google Scholar 

  18. Yavari R, Adida C, Bray-Ward P, Brines M, Xu T (1998) Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia. Hum Mol Genet 7:1161–1167

    Article  CAS  PubMed  Google Scholar 

  19. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A et al (2003) L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 362:869–875

    Article  CAS  PubMed  Google Scholar 

  20. McCulloch DR, Akl P, Samaratunga H, Herington AC, Odorico DM (2004) Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin Cancer Res 10:314–323

    Article  CAS  PubMed  Google Scholar 

  21. Tanida S, Joh T, Itoh K, Kataoka H, Sasaki M, Ohara H et al (2004) The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 127:559–569

    Article  CAS  PubMed  Google Scholar 

  22. Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T et al (2007) Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 67:7703–7712

    Article  CAS  PubMed  Google Scholar 

  23. Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW, Liu TY (2007) Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett 245:33–43

    Article  CAS  PubMed  Google Scholar 

  24. Soundararajan R, Sayat R, Robertson GS, Marignani PA (2009) Triptolide: an inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. Cancer Biol Ther 8(21):2054–2062

    Article  CAS  PubMed  Google Scholar 

  25. Wolfsberg TG, Primakoff P, Myles DG, White JM (1995) ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 131:275–278

    Article  CAS  PubMed  Google Scholar 

  26. Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17:7–30

    Article  CAS  PubMed  Google Scholar 

  27. Lunn CA, Fan X, Dalie B, Miller K, Zavodny PJ, Narula SK et al (1997) Purification of ADAM 10 from bovine spleen as a TNFalpha convertase. FEBS Lett 400:333–335

    Article  CAS  PubMed  Google Scholar 

  28. Millichip MI, Dallas DJ, Wu E, Dale S, McKie N (1998) The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 245:594–598

    Article  CAS  PubMed  Google Scholar 

  29. Hattori M, Osterfield M, Flanagan JG (2000) Regulated cleavage of a contact-mediated axon repellent. Science 289:1360–1365

    Article  CAS  PubMed  Google Scholar 

  30. Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S et al (2001) Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 155:661–673

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W et al (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11:2615–2624

    Article  CAS  PubMed  Google Scholar 

  32. Lemjabbar H, Basbaum C (2002) Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 8:41–46

    Article  CAS  PubMed  Google Scholar 

  33. Yan Y, Shirakabe K, Werb Z (2002) The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 158:221–226

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 [fractalkine] and regulates CX3CL1-mediated cell-cell adhesion. Blood 102:1186–1195

    Article  CAS  PubMed  Google Scholar 

  35. Nagano O, Murakami D, Hartmann D, de Strooper B, Saftig P, Iwatsubo T et al (2004) Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 165:893–902

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D et al (2005) ADAM10 cleavage of N-cadherin and regulation of cell–cell adhesion and beta-catenin nuclear signalling. EMBO J 24:742–752

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Sanderson MP, Erickson SN, Gough PJ, Garton KJ, Wille PT, Raines EW et al (2005) ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J Biol Chem 280:1826–1837

    Article  CAS  PubMed  Google Scholar 

  38. Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S et al (2006) ADAM10 is a principal ‘sheddase’ of the low-affinity immunoglobulin E receptor CD23. Nat Immunol 7:1293–1298

    Article  CAS  PubMed  Google Scholar 

  39. Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 98:621–628

    Article  CAS  PubMed  Google Scholar 

  40. Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A et al (2009) MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS ONE 4:e7405

    Article  PubMed Central  PubMed  Google Scholar 

  41. Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K, Ren G, Su T, Pan Y, Feng B, Xue Z, Wang X, Fan D (2010) MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun 392(3):340–345

    Article  CAS  PubMed  Google Scholar 

  42. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W (2006) Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 125:1111–1124

    Article  CAS  PubMed  Google Scholar 

  43. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:685–689

    Article  PubMed  Google Scholar 

  44. Esau C, Davis S, Murray SF, Yu XX, Pandey SK et al (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3:87–98

    Article  CAS  PubMed  Google Scholar 

  45. Bai S, Nasser MW, Wang B, Hsu SH, Datta J et al (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284:32015–32027

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Wang B, Wang H, Yang Z (2012) MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS ONE 7(10):e47053

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Wolff AC, Hammond MEH, Hicks DG, Dowsett M et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. JCO 31(31):3997–4013

    Article  Google Scholar 

  48. Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa KT, Sun G, Wang Y, Smith R, Robinson K, Ren X, Wang SE (2012) De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 10:42

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM et al (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137:1032–1046

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Munagala R, Aqil F, Vadhanam MV, Gupta RC (2013) MicroRNA ‘signature’ during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. Cancer Lett 339(2):175–184

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Zhou B-BS, Petyon M, He B et al (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10:39–50

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Fridman JS, Caulder E, Hansbury M et al (2007) Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 13:1892–1902

    Article  CAS  PubMed  Google Scholar 

  53. Infante J, Burris HA, Lewis N et al (2007) A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. Breast Cancer Res Treat 106(Supp1):S269

    Google Scholar 

  54. Witters L, Scherle P, Friedman S et al (2008) Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 68:7083–7089

    Article  CAS  PubMed  Google Scholar 

  55. Newton RC, Bradley EC, Levy RS et al (2010) Clinical benefit of INCB7839, a potential and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2-positive breast cancer. J Clin Oncol 28(Suppl; abst 3025):7s

  56. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J (2014) Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res 42(1):609–621

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Hundhausen C, Misztela D, Berkhout TA, et al (2003) The disintegrinlike metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1mediated cellcell adhesion. Blood 102(4):1186–1195

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Şehitkamil, 27310, Gaziantep, Turkey

    Sercan Ergün, Mustafa Ulasli, Yusuf Ziya Igci, Mehri Igci, Sevil Kırkbes, Ecir Ali Cakmak, Ahmet Arslan & Serdar Oztuzcu

  2. Department of General Surgery, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey

    Ersin Borazan & Ahmet Balik

  3. Department of Medical Biology, Faculty of Medicine, Adıyaman University, Adıyaman, Turkey

    Önder Yumrutaş

  4. Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey

    Celalettin Camci

Authors
  1. Sercan Ergün
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mustafa Ulasli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuf Ziya Igci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehri Igci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sevil Kırkbes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ersin Borazan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ahmet Balik
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Önder Yumrutaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Celalettin Camci
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ecir Ali Cakmak
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ahmet Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Serdar Oztuzcu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sercan Ergün.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ergün, S., Ulasli, M., Igci, Y.Z. et al. The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol Biol Rep 42, 497–505 (2015). https://doi.org/10.1007/s11033-014-3793-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3793-2

Keywords

Search

Navigation